Mar 03, 2020
Sierra Oncology Reports 2019 Year End Results
Feb 26, 2020
Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call
Feb 25, 2020
Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference
Feb 06, 2020
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead
Jan 22, 2020
Sierra Oncology Announces Reverse Stock Split
Dec 07, 2019
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
Dec 02, 2019
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH
Nov 26, 2019
Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors
Nov 20, 2019
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
Nov 14, 2019
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference
Nov 07, 2019
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib
Nov 07, 2019
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants
Nov 06, 2019
Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants
Nov 06, 2019
Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019
Nov 04, 2019
Sierra Oncology Reports Third Quarter 2019 Results
Aug 08, 2019
Sierra Oncology Reports Second Quarter 2019 Results
Aug 07, 2019
Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York
Jun 27, 2019
Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets
Jun 05, 2019
Sierra Announces Momelotinib Granted FDA Fast Track Designation
Jun 04, 2019
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial